Insider buying last 90 days
No open-market insider purchases were filed for OCUL in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every OCUL insider filing, plotted on the chart in Gekko.Open OCUL in Gekko
NASDAQ: OCUL
Ocular Therapeutix (OCUL) Stock Analysis & Forecast
Oct 12 close
$7.56+0.02 (+0.3%)
Gekko Brief
AI summaryOct 12 closeThis week's news centers on fresh analyst attention toward Ocular Therapeutix's lead asset, Axpaxli. UBS initiated coverage with a Buy rating and a $14.00 price target, citing Axpaxli's potential as a long-acting retinal therapy addressing a projected $20 billion U.S. market. The company also reported a Q2 loss of $0.35 per share on revenues of $13.5 million, narrower than consensus estimates, and noted plans to submit a new drug application for AXPAXLI in wet AMD in the fourth quarter while streamlining its HELIOS-3 diabetic retinopathy study.
OCUL closed at $7.56, down between its 50-day average of $9.64 and 200-day average of $9.45, reflecting a mixed trend. Shares have fallen 27.9% over one month and 36.7% over one year, with a 52-week range of $6.23 to $16.44. The GekkoIndex reads 66.8, placing the stock in the Accumulation zone, down 8.6 points over five days. The current price sits 43.2% below the Gekko Fair Value of $13.3.
Looking ahead, OCUL reports earnings on 3 November, 21 days out and within a typical 20-trading-day holding window; the prior quarter saw a 5.1% reaction with an average absolute move of 7.5% across the last eight quarters. Seasonality over the past 5 years shows an average 20-day return of -7.5% from this point in the calendar, with gains in only 1 of those years. No insider, Congress, or options activity is recorded in the respective 90-day and 30-day windows, though a trailblazer holder is noted among institutional positions.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Ocular Therapeutix price vs fair value
Close $7.56200-day averageGekko Fair Value $13.30
Ocular Therapeutix quick facts
- Market cap
- $1.66B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$1.40
- Revenue, TTM
- $52.06M
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 0.99
- Volume
- 3.67M avg 3.91M
- 1-year return
- −36.7%
- Typical daily move
- ±8%
- Typical 20-day move
- ±14.2%
- 50-day average
- $9.64
- 200-day average
- $9.45
- Next earnings
- Nov 3 before open
- Shares outstanding
- 219.6M
Ocular Therapeutix swing-trade checklist
Ocular Therapeutix scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
- Trendmixed
Averages disagree
Close $7.56 sits between the 50-day ($9.64) and 200-day ($9.45) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
66.8, Accumulation
Reading 66.8 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
43.2% below
Price is 43.2% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 22 days
Reports on Nov 3, 2026, 22 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−7.5% on average
From this point in the calendar, the next 20 trading days averaged −7.5% over 5 years, rising in 1 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Ocular Therapeutix stock chart and price history
Ocular Therapeutix closed at $7.56 on Oct 12, 2026, −36.7% over the past year, inside a 52-week range of $6.23 to $16.44.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −27.9%
- 3 months
- −22.1%
- 6 months
- −14.7%
- 1 year
- −36.7%
The full OCUL chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open OCUL in Gekko
Follow Ocular Therapeutix through every session
Put OCUL on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track OCUL in GekkoFree for 7 days. No credit card required.
About Ocular Therapeutix
Ocular Therapeutix works on treatments for diseases and conditions of the eye, built around a bioresorbable hydrogel platform of its own design. Two products have reached the market under this approach: ReSure Sealant, used to stop fluid leakage from corneal incisions following cataract surgery, and DEXTENZA, an insert that delivers dexamethasone to manage pain and inflammation after eye surgery and to treat allergic conjunctivitis.
Beyond these marketed products, the company has a pipeline of candidates at different clinical stages, covering areas such as wet age-related macular degeneration, glaucoma, ocular hypertension and dry eye disease. It also works with outside partners to extend its reach: Regeneron Pharmaceuticals on combining the hydrogel technology with VEGF-targeting compounds for retinal disease, AffaMed Therapeutics on commercializing DEXTENZA and one of its pipeline candidates, and Mosaic Biosciences on early-stage discovery work aimed at dry age-related macular degeneration.
Founded in 2006, Ocular Therapeutix is headquartered in Bedford, Massachusetts. Its shares are listed on the NASDAQ under the ticker OCUL.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- ocutx.com
Ocular Therapeutix GekkoIndex: the smart money zone
Ocular Therapeutix’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 66.8, in the Accumulation zone, down 8.6 points over five sessions.
66.8Accumulation
Down 8.6 points over five sessions, from the Buying zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 43 | +7.5% | +17.2% | ||
| Accumulation (current zone) | 210 | −1.1% | +4.3% | ||
| Neutral | 379 | +1.1% | +1.7% | ||
| Distribution | 42 | +2.6% | +16.4% | ||
| Selling | 8 | Too few readings yet | |||
Average OCUL share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the OCUL price, zone by zone.Track OCUL in Gekko
Is Ocular Therapeutix stock overvalued? Gekko Fair Value
Ocular Therapeutix trades 43.2% below Gekko Fair Value of $13.30, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Ocular Therapeutix shares are worth, recalculated every trading day.
$13.30
Gekko Fair Value, Oct 10, 2026
43.2% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open OCUL in Gekko
Ocular Therapeutix insider and Congress trading
No open-market insider purchases were filed for Ocular Therapeutix, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in OCUL were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for OCUL, plotted on the chart in Gekko.Open OCUL in Gekko
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds OCUL.
0added0opened1trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Ocular Therapeutix earnings: next date and track record
Ocular Therapeutix reports on Nov 3, 2026, before the open (22 days away), and beat the EPS estimate in 3 of its last 8 reports.
Next earnings report
Nov 3, 2026
Expected before the open, 22 days away
- EPS estimate
- −$0.36
- Revenue estimate
- $14.32M
3 of 8reports beat the EPS estimate
±7.5%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 3, 2026 | −$0.35 est −$0.40 | $13.48M est $13.20M | +5.1% |
| May 5, 2026 | −$0.40 est −$0.31 | $10.79M est $12.72M | −0.6% |
| Feb 5, 2026 | −$0.29 est −$0.32 | $13.25M est $16.13M | +7.1% |
| Nov 4, 2025 | −$0.37 est −$0.39 | $14.54M est $16.14M | −5.3% |
| Aug 5, 2025 | −$0.39 est −$0.35 | $13.46M est $14.57M | +1.2% |
| May 5, 2025 | −$0.37 est −$0.28 | $10.63M est $13.10M | −18.4% |
| Mar 3, 2025 | −$0.29 est −$0.22 | $17.08M est $17.11M | −9.0% |
| Nov 14, 2024 | −$0.22 est −$0.21 | — | −13.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Ocular Therapeutix stock forecast and analyst price targets
Analysts’ average 12-month price target for Ocular Therapeutix is $27.09, +258.3% from the last close, from 9 firms rating the stock in the last 90 days.
$27.09consensus 12-month target, +258.3% from the last close
Now $7.56Avg $27.09
Low $14High $31
Each firm’s latest rating in the last 90 days: 9 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 12 | UBS | $14 | +85.2% |
| Oct 12 | Piper Sandler | $31 | +310.1% |
| Oct 11 | UBS | $14 | +85.2% |
| Sep 29 | Piper Sandler | $31 | +310.1% |
| Sep 28 | Needham | $18 | +138.1% |
+4.3%average 20-day move after past Accumulation readings
−7.5%average move over the next 20 trading days in the last 5 years
±8%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Ocular Therapeutix seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Ocular Therapeutix averaged −7.5% across the last 5 years, rising in 1 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +5.2% | 4 of 5 |
| Next 10 trading days | −8.2% | 1 of 5 |
| Next 15 trading days | −5.5% | 2 of 5 |
| Next 20 trading days | −7.5% | 1 of 5 |
| Next 30 trading days | −18.3% | 1 of 5 |
For scale, OCUL’s typical 20-trading-day move in either direction is about 14.2%.
Ocular Therapeutix market cap and key statistics
Ocular Therapeutix’s market cap is $1.66B and revenue of $52.06M over the last twelve months.
Valuation
- Market cap
- $1.66B
- EPS, TTM
- −$1.40
- Gekko Fair Value
- $13.30
Trading
- Volume
- 3.67M
- Avg volume, 20 days
- 3.91M
- 52-week high
- $16.44
- 52-week low
- $6.23
- Shares outstanding
- 219.6M
Financials
- Revenue, TTM
- $52.06M
- Profit margin
- 0%
- Return on equity
- -73%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.99
- Typical daily move
- ±8%
- Typical 20-day move
- ±14.2%
Ocular Therapeutix stock news this week
Coverage of Ocular Therapeutix this week reads neutral: 3 positive, 10 neutral and 0 negative headlines.
- OCUL Initiates Coverage On UBS -- Price Target Announced at $14.00GuruFocus, Oct 12
- UBS initiates Ocular Therapeutix stock with buy rating on Axpaxli potentialInvesting.com, Oct 12
- Total debt per share of Ocular Therapeutix Inc – HAN:0OTTradingView, Oct 12
- Form 144 OCULAR THERAPEUTIX For: 10 October By Investing.comInvesting.com Canada, Oct 10
- 15 new hires receive stock awards from Ocular TherapeutixStock Titan, Oct 9
- Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)The Manila Times, Oct 9
Ocular Therapeutix peers
Ocular Therapeutix’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 14.7% above |
| JNJJohnson & Johnson | Neutral | 3.2% below |
| ABBVAbbVie | Distribution | 28.2% above |
| MRKMerck | Neutral | 8.0% below |
| AZNAstraZeneca | Accumulation | 41.7% below |
| PFEPfizer | Neutral | 8.0% below |
A peer links to its own page where one exists.
Ocular Therapeutix stock FAQ
What is Ocular Therapeutix’s market cap?
Ocular Therapeutix’s market cap is $1.66B at the Oct 12, 2026 close of $7.56, with 219.6M shares outstanding.
What is the Ocular Therapeutix stock forecast?
The consensus analyst 12-month price target for Ocular Therapeutix is $27.09, +258.3% from the last close. Of the 9 firms that rated the stock in the last 90 days, 9 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Ocular Therapeutix stock overvalued or undervalued?
On Gekko’s estimate Ocular Therapeutix is undervalued: the Oct 12, 2026 close of $7.56 is 43.2% below Gekko Fair Value of $13.30. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Ocular Therapeutix report earnings next?
Ocular Therapeutix is expected to report on Nov 3, 2026, before the market opens (22 days away). Analysts expect earnings of −$0.36 per share on revenue of $14.32M. Ocular Therapeutix beat the earnings estimate in 3 of its last 8 reports, moving 7.5% on average across the report.
What is Ocular Therapeutix’s 52-week high and low?
Ocular Therapeutix’s 52-week high is $16.44 and its 52-week low is $6.23; it closed at $7.56 on Oct 12, 2026, −36.7% over the past year.
Is Ocular Therapeutix stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (gekkoindex and fair value), 1 as mixed (trend) and 2 as headwinds (earnings risk and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Ocular Therapeutix the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.